To investigate the inhibitory effect of Ani9 on endogenous CaCCs, we observed the inhibition of endogenous CaCCs activity by Ani9 in PC3 human prostate cancer cells, Capan-1 human pancreatic cancer cells and IL-4 treated NHNE cells because PC3, Capan-1 and IL-4 treated human primary airway epithelial cells highly express endogenous ANO1 [40–42]. The gene discussed is IL4; the disease is Familial prostate cancer.